Primary study · included by 1 review

Dinan 2022

ProbableThe reviews cited this study without a PMID, DOI or NCT, so it is matched by first author and year. Two different studies by the same author in the same year could be merged here.

Included by

Adherence to oral antineoplastic agents, an overview and meta-analysis.

Non-Cochrane · prevalence · 2026 · cited as Dinan 2022 · Table 3; Figure 2

Outcome this study informs	Pooled effect	Evidence	Certainty
Cumulative adherence Adherence measured objectively (MEMS, MPR or PDC) · Study durations varied (<6 months and >=6 months)	Pooled proportion (random-effects, logit) 0.84 [0.78, 0.89]	17 studies · 7262 participants	GRADE not reported
Lower-bound adherence (proportion of patients above an 80%, 85% or 90% adherence threshold) Adherence measured objectively (MEMS, MPR or PDC) · Study durations varied	Pooled proportion (random-effects, logit) 0.71 [0.63, 0.78]	20 studies · 31230 participants	GRADE not reported

1 including review in total.